Drug Utilisation of Mysimba/Contrave

Completed

Conditions studied: Obesity

In brief

This study will assess a retrospective cohort of users of Mysimba/Contrave with up to 548 days (\~18 months) after initiation with treatment with Mysimba/Contrave. This study will describe Mysimba/Contrave utilisation and incidence of AESIs for users compliant and non-compliant with the SmPC.

Key facts

Study ID

NCT06089824

Run by

Currax Pharmaceuticals

People needed

43324

Starts

2014-09-01

Expected to finish

2022-10-01

Last updated by the study team

2023-10-18

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least one prescription of Mysimba/Contrave in his/her medical records any time during the study period (US) OR at least one dispensing of Mysimba/Contrave in his/her registry any time during the study period (Nordic);
• At least 365 days of computerized records prior to first Mysimba/Contrave prescription or dispensing date; and3Patient is active (i.e., alive and registered/accruing data) at the time of the first Mysimba/Contrave prescription or dispensing date.

You may not qualify if…

• All patients meeting inclusion criteria will be included in the study; no exclusion criteria will be applied.

Where it is running

• Currax Pharmaceuticals — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.